Skip to main content
Premium Trial:

Request an Annual Quote

Complete Genomics Reports $4.2M in Third-Quarter Revenue

Premium

This article has been updated to correct the operating expenses for the third quarter of 2009.

As it is preparing for its initial public offering, Complete Genomics this week reported $4.2 million in revenue for the third quarter, along with a net loss of $20.5 million.

The company had no revenue during the third quarter of 2009, and a $9.25 million net loss.

As previously stated, Complete Genomics had $9 million worth of backlog orders as of Sept. 30, for which it expects to bill customers within the next 12 months.

The company had operating expenses of $14.9 million during the quarter, up from $8.6 million during the year-ago quarter. As of Sept. 30, it had $10.5 million in cash and cash equivalents.

Last month, Complete Genomics raised its maximum aggregate offering price for its planned IPO to $96.6 million, from an earlier target of $86.25 million (IS 10/26/2010).

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.